Previous 10 | Next 10 |
Noteworthy events during the week of January 19 - 25 for healthcare investors. More news on: Epizyme, Inc., Nevro Corp., Generex Biotechnology Corporation, Healthcare stocks news, , Read more ...
Shares of CD47 front-runner Forty Seven ( FTSV ) have risen by 120% over the past year and by 525% over the past three months. Currently, this growing biotech firm sports a market capitalization of around $1.75 billion, with management executing quite efficiently on accessing financing in ...
-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b Trial in Higher-Risk MDS and AML Expected Mid-Year 2020 -- -- Initial Data from P...
Cinderella stories aren't common in investing, but they do happen. Perhaps the best recent example is Axsome Therapeutics (NASDAQ: AXSM) . The company's market cap dipped to just $60 million in the final days of 2018, but promising results from a drug candidate aimed at treating depres...
Investment Thesis Forty Seven ( FTSV ) management must be pleased with the progress they made in December '19. First of all, early results from clinical trials of the company's flagship drug magrolimab were positive. In a trial evaluating magrolimab in combination with azacitidine for ...
The annual American Society of Hematology (ASH) conference has historically been fertile ground for revolutionary advances in the treatment of blood disorders and cancers. This year was no exception. Among the thousands of presentations at the conference, a number of groundbreaking advances were...
2020 should be another favorable year for healthcare investing, though the gains thus far in 2019 should necessitate greater selectivity. The overriding investment theme in healthcare, in my opinion, is the fact that the dual tailwinds of the aging of the population and the obesity epidemic (b...
Shares of Forty Seven (NASDAQ: FTSV) rose more than 18% today after the company announced the pricing of a public stock offering. The biopharma will issue up to 5.59 million shares of common stock at $35 apiece. The offering will raise up to $195.6 million in gross proceeds. Why would...
Forty Seven (NASDAQ: FTSV ) has priced its public offering of 4.86M common shares at $35.00 per share, for expected gross proceeds of $170.1M. More news on: Forty Seven, Inc., Healthcare stocks news, Read more ...
MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 p...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...